Article
The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy.
Journal of Alzheimer's disease : JAD - 1 Jan 2020
Rao Shalini S, Portbury Stuart D, Lago Larissa, Bush Ashley I, Adlard Paul A
Abstract excerpt
BACKGROUND: Abnormally hyperphosphorylated tau is a defining pathological feature of tauopathies, such as Alzheimer's disease (AD), and accumulating evidence suggests a role for iron in mediating tau pathology that may lead to cognitive decline in these conditions. The metal chelator deferiprone (DFP), which has a high affinity for iron, is currently in clinical trials for AD and Parkinson's disease. However, the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
